AlenCiken

Reduced recovery time in mild-to-moderate COVID-19 patients

NASDAQ:CDXC   ChromaDex Corporation
New Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients

New Phase 3 study results show added nutritional protocol reduces recovery time in mild-to-moderate COVID-19 patients

The addition of the nutritional protocol, or combined metabolic activators (CMA), to the Turkish standard of care not only reduced recovery time but improved liver health and decreased levels of inflammatory markers.

finance.yahoo.com/ne...finds-113000203.html

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.